Keywords
How to Cite
Abstract
This article discusses the role of neoadjuvant chemotherapy in osteosarcoma and contemporary approaches to assessing treatment effectiveness. Osteosarcoma is a primary malignant bone tumor characterized by aggressive growth and metastatic potential. Its treatment commonly combines systemic chemotherapy with surgical resection. Neoadjuvant chemotherapy aims to treat tumor cells before surgery, support treatment planning and address potential micrometastatic disease. Its effectiveness is assessed using magnetic resonance imaging, computed tomography, clinical evaluation and postoperative histopathological examination. In particular, the percentage of tumor necrosis in the resected specimen is an important measure of pathological response and a prognostic indicator. The article reviews assessment criteria, their advantages and limitations, and opportunities to improve treatment evaluation.
References
1. Strauss S. J., Frezza A. M., Abecassis N. et al. Bone sarcomas: ESMO–EURACAN–GENTURIS–ERN PaedCan Clinical Practice Guideline for diagnosis, treatment and follow-up. Annals of Oncology. 2021;32(12):1520–1536.
2. Bielack S. S., Kempf-Bielack B., Delling G. et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. Journal of Clinical Oncology. 2002;20(3):776–790.
3. Isakoff M. S., Bielack S. S., Meltzer P., Gorlick R. Osteosarcoma: current treatment and a collaborative pathway to success. Journal of Clinical Oncology. 2015;33(27):3029–3035.
4. Picci P., Bacci G., Campanacci M. et al. Histologic evaluation of necrosis in osteosarcoma induced by chemotherapy: regional mapping of viable and nonviable tumor. Cancer. 1985;56(7):1515–1521.
5. Eisenhauer E. A., Therasse P., Bogaerts J. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). European Journal of Cancer. 2009;45(2):228–247.
6. Marina N. M., Smeland S., Bielack S. S. et al. Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial. The Lancet Oncology. 2016;17(10):1396–1408.